The combination of trastuzumab and platinum-based chemotherapy tested in ToGA trial has established itself as the standard-of-care treatment for HER2-positive GC, significantly improving survival outcomes for patients with advanced disease [16]. This evidence concerns the gene ERBB2 and gastric cancer.